Phase 2 Parkinson's Disease Trial, Recruiting NCT06530290 Sponsor: Leila Dargahi. PharmD PhD Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 2 Parkinson's Disease Trial, Recruiting

NCT06530290
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older (both men and women)
  • People who have been diagnosed with Parkinson's disease using a specific set of recognised diagnostic standards (known as UKPDSBB criteria)
  • People with mild to moderate Parkinson's disease, based on a standard rating scale called the Hoehn and Yahr Scale (scores 1 to 3)
  • People who either self-report anxiety or have received a clinical diagnosis of anxiety
  • People who have signed a consent form agreeing to take part in the study

Who may not be able to join:

  • Women who are pregnant or breastfeeding
  • People whose Parkinson's disease was diagnosed less than one year ago
  • People whose Parkinson's disease medication has changed or been unstable in the last two weeks
  • People with Parkinson's disease who have a deep brain stimulation (DBS) device
  • People who have another neurological degenerative condition, such as multiple system atrophy or Huntington's disease
  • People who have been diagnosed with major depressive disorder
  • People who have used certain medications — including SSRIs, SNRIs, benzodiazepines, or beta-blockers — in the last four weeks
  • People who have a history of using MAO inhibitor medications
  • People who have a history of alcohol or substance abuse
  • People who have experienced acute (sudden or severe) stress in the last three months
  • People who have a history of suicide
  • People who have a history of cardiovascular (heart or blood vessel) disease
  • People who have a history of liver or kidney disorders

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Leila Dargahi, PharmD/PhD, Shahid Beheshti University of Medical Sciences

Phone: +989125069930

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Leila Dargahi. PharmD PhD
Registry
ClinicalTrials.gov
Start date
1 June 2022
Est. completion
20 December 2025

Where this trial is recruiting

Iran

Primary endpoints

Anxiety score; Anxiety score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov